Thomas A Dahl (Thomas Dahl)

Publication Activity (10 Years)

Years Active: 2019-2023
Publications (10 Years): 6

Top Topics

Blood Brain Barrier

Respiratory Tract

Top Venues

Human psychopharmacology

Sleep and biological rhythms

Clinical case reports

Clinics and practice

This page only lists publications with an associated author ORCID identifier.

Publications

Emina Išerić, Thomas A Dahl, Andrew Scholey, Jacqueline M Iversen, Joris C Verster
The efficacy of a combination of naproxen and fexofenadine (SJP - 002) to inhibit the symptoms that are associated with viral upper respiratory tract infection: Four case reports of individuals with common cold. Clinical case reports 11 (7) (2023)
Pantea Kiani, Thomas A Dahl, Jacqueline M Iversen, Andrew Scholey, Joris C Verster
Efficacy of Naproxen/Fexofenadine (SJP-003) in the Prevention of Side Effects of Influenza Vaccination: Four Case Studies. Clinics and practice 12 (5) (2022)
Thomas A Dahl, Gary Zammit, Maha Ahmad, Russell Rosenberg, Lan Bo Chen, Thomas Roth
Efficacy of the triple-combination SM-1 in a 5-h phase advance transient insomnia model. Sleep and biological rhythms 20 (1) (2021)
Thomas A Dahl, Gary Zammit, Maha Ahmad, Russell Rosenberg, Lan Bo Chen, Thomas Roth
Efficacy of the triple-combination SM-1 in a 5-h phase advance transient insomnia model. Sleep and biological rhythms 20 (1) (2021)
Thomas A Dahl, Lan Bo Chen, Gary Zammit, Maha Ahmad, Thomas Roth
Efficacy of SM-1 in a transient insomnia model. Human psychopharmacology 34 (6) (2020)
Thomas A Dahl, Lan Bo Chen, Mika Scheinin, Jaana Suopanki-Lalowski, Marju Valge, Antti Puhakka, Hannu Mikola, Zsófia Lovró, Axel Meierjohann, Lauri Vuorilehto, Thomas Roth
Pharmacodynamic and pharmacokinetic profile of SM-1, a triple-drug combination to increase total sleep time. Human psychopharmacology 34 (6) (2019)